Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Adding a third anti-malaria drug to current artemisinin-combination therapies (ACTs) provides effective treatment against multidrug-resistant falciparum malaria in Southeast Asia, say Oxford researchers in a study in The Lancet. Using TACTs should extend current malaria drugs so drug-resistant malaria doesn't kill millions more and derail hopes of controlling and eliminating malaria.

People being recruited for the TRAC II study in Kinshasa © MORU 2020. Photographer: Mehul Dhorda
Recruitment for the TRAC II study in Kinshasa, DR Congo.
Load More

Similar stories

Real-time genetic surveillance can support timely, evidence-based responses to shifting malaria threats

A sharp decline in piperaquine-resistant strains of P. Falciparum malaria following drug policy revisions across the Greater Mekong Subregion (GMS) highlights how real-time genetic data can support timely, evidence-based responses to shifting malaria threats, say researchers in a study published in Nature Communications.